Loading...

Home
Stock
RXRX

RXRX Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

3.070

Open

2.900

VWAP

3.01

Vol

13.92M

Mkt Cap

1.62B

Low

2.900

Amount

41.96M

EV/EBITDA(TTM)

--

Total Shares

527.40M

EV

894.47M

EV/OCF(TTM)

--

P/S(TTM)

18.39

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Show More

Events Timeline

(ET)

2026-03-25

08:10:00

Recursion Appoints Vicki Goodman as Chief Medical Officer

2026-03-05 (ET)

2026-03-05

08:50:00

Klarna Group Borrow Rate Increases to 31.14%

2026-03-05

08:50:00

PacBio Appoints Dr. Christopher Gibson to Board of Directors

2026-02-25 (ET)

2026-02-25

06:40:00

Recursion Reports Q4 Revenue of $35.5M, Exceeding Expectations

2026-02-12 (ET)

2026-02-12

08:10:00

Recursion Grants 820,431 Inducement RSUs to 17 New Employees

2026-01-30 (ET)

2026-01-30

10:50:00

Nvidia, Amazon, and Microsoft Plan to Invest Up to $60B in OpenAI

News

Fool

Investment Opportunities and Risks in Artificial Intelligence

AI Technology Transformation: Artificial intelligence is viewed as a transformative technology that could trigger paradigm shifts across various industries; while some companies have capitalized on investments, the overall sector is still in its early stages, presenting ongoing investment opportunities.
Alphabet's AI Strategy: Alphabet has integrated AI modes and overviews into its search engine, boosting search traffic and user engagement, and although its stock has fallen 13% due to market volatility, its AI investments help solidify its market position.
Recursion's Challenges: Recursion Pharmaceuticals focuses on leveraging AI to accelerate drug development, claiming to shorten clinical trial times, yet it has not launched any products and remains unprofitable, posing significant risks.
Investment Risk Assessment: While Recursion could achieve breakthroughs in the future, the lack of market products and profitability suggests that investors with average risk tolerance should approach this stock with caution.

NASDAQ.COM

13:03 PMNASDAQ.COM

Analysis of AI Prospects for Alphabet and Recursion

Alphabet's AI Investment: Despite a 13% drop in Alphabet's stock this year, its substantial investments in AI are enhancing search engine traffic and user engagement, demonstrating the company's strong competitive advantage.
Market Volatility Impact: While Alphabet's financial performance remains robust, broader market volatility and concerns over AI investment returns are causing investor caution, potentially affecting future stock performance.
Recursion's Challenges: Recursion Pharmaceuticals has yet to launch any market products, and although it claims to accelerate drug development through AI, the lack of successful clinical trials poses high risks, making it a cautious choice for average investors.
Investment Recommendation: Although Alphabet did not make the Motley Fool's list of the top 10 stocks to buy, its diversified growth avenues and strong brand equity still position it as a quality stock worth holding long-term.

CNBC

Goldman Sachs Optimistic on Nvidia's AI Healthcare Prospects

Positive Market Outlook: Goldman Sachs' buy rating on Nvidia and a $250 price target imply a 51% upside, reflecting investor confidence in its AI applications within healthcare and life sciences.
Collaborative Technological Edge: By partnering with life sciences companies, Nvidia can validate its models in labs, leveraging digital twins and simulation to enhance the quality of experiments and manufacturing while reducing costs, thereby strengthening its market position.
Investment and Applications: In 2023, Nvidia invested $50 million in clinical-stage biotech firm Recursion Pharmaceuticals to develop AI models for accelerating drug discovery, driving technological advancements in the biopharma sector.
Clinical Trial Efficiency Gains: Recursion's AI technology enables drugmakers to synthesize 90% fewer compounds and reduces the average time to enter human trials from 42 months to 17 months, significantly improving research and development efficiency.

Fool

AI's Promising Applications in Healthcare

Reduced Drug Development Costs: Recursion Pharmaceuticals leverages over 50 petabytes of chemical and biological data through its AI platform to help pharmaceutical companies assess drug performance in hours, significantly lowering the traditional R&D costs close to $900 million, thereby enhancing resource efficiency.
Strengthened Partnerships: Recursion's collaboration with traditional pharma giants like Sanofi and Roche to conduct virtual testing has driven revenue growth, with expectations of a larger revenue influx in the next fiscal year, indicating its potential in the AI drug development market.
Tempus AI's Market Performance: Tempus AI empowers healthcare providers with real-time data-driven decision support, achieving fourth-quarter revenue of $367 million, an 83% year-over-year increase, demonstrating strong market demand and customer satisfaction.
Future Growth Expectations: Analysts have set a target price of $77.93 for Tempus, which is 70% above its current price, reflecting market optimism regarding its future profitability and further enhancing its investment appeal.

NASDAQ.COM

03-27NASDAQ.COM

Recursion Pharmaceuticals Stock Decline Analysis

Stock Performance: Recursion Pharmaceuticals (RXRX) closed at $2.94, down 6.67% from the previous session, significantly underperforming the S&P 500's 1.67% decline, indicating weakness in market sentiment towards the company.
Monthly Decline: The stock has fallen 16.45% over the past month, greatly exceeding the Medical sector's 7.36% and the S&P 500's 6.15% losses, reflecting investor concerns regarding its future profitability.
Earnings Expectations: The upcoming earnings report is expected to show an EPS of -$0.27, a 46% increase from the prior year, with revenue projected at $20.73 million, up 40.65% year-over-year, indicating potential business growth.
Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Recursion's EPS estimate has increased by 9.98% in the last 30 days, suggesting analysts' growing confidence in the company's short-term performance, despite its industry ranking being in the bottom 40% of over 250 sectors.

seekingalpha

03-25seekingalpha

Recursion Appoints New Chief Medical Officer

Executive Change: Recursion announced the appointment of Vicki Goodman as Chief Medical Officer, effective April 6, 2026, succeeding David Mauro; Goodman brings over 20 years of oncology drug development experience, having most recently served as CMO at Mural Oncology, where she advanced its pipeline.
Extensive Industry Background: Goodman has held senior oncology roles at Merck and Bristol Myers Squibb, leading the development of key drugs such as Keytruda, Opdivo, and Yervoy, showcasing her deep expertise in cancer therapeutics.
Market Reaction: Following the announcement of this executive change, Recursion's shares fell by 1.86%, indicating market uncertainty regarding the new CMO's impact and investors' cautious outlook on the company's strategic direction.
Future Outlook: Recursion expects to extend its cash runway into early 2028 while enhancing operational efficiency; although the executive transition may affect short-term market confidence, the long-term strategy remains focused on innovative drug development.

Wall Street analysts forecast RXRX stock price to rise

6 Analyst Rating

Wall Street analysts forecast RXRX stock price to rise

2 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

7.75

High

11.00

Current: 0.000

Low

5.00

Averages

7.75

High

11.00

BofA

Neutral

downgrade

$7 -> $6

AI Analysis

2026-02-26

Reason

BofA

Price Target

$7 -> $6

AI Analysis

2026-02-26

downgrade

Neutral

Reason

BofA lowered the firm's price target on Recursion Pharmaceuticals to $6 from $7 and keeps a Neutral rating on the shares. The firm revised its estimates, updated operating expense and share count and pushed back the REC-617 launch timing, driving its lowered price target.

JPMorgan

Neutral -> Overweight

upgrade

$10 -> $11

2025-12-17

Reason

JPMorgan

Price Target

$10 -> $11

2025-12-17

upgrade

Neutral -> Overweight

Reason

JPMorgan upgraded Recursion Pharmaceuticals to Overweight from Neutral with a price target of $11, up from $10. The firm says the company's REC-4881 has shown "strong and durable" efficacy in familial adenomatous polyposis. REC-4881's addressable market is now broader than previously expected, creating blockbuster potential, the analyst tells investors in a research note. JPMorgan sees peak sales of over $1B and a 60% probability of success. In addition, Recursion's REC-617, a CDK7 inhibitor, has shown early anti-tumor activity in platinum-resistant ovarian cancer, says JPMorgan.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RXRX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Recursion Pharmaceuticals Inc (RXRX.O) is -3.38, compared to its 5-year average forward P/E of -7.39. For a more detailed relative valuation and DCF analysis to assess Recursion Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-7.39

Current PE

-3.38

Overvalued PE

-1.23

Undervalued PE

-13.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-6.37

Current EV/EBITDA

-2.84

Overvalued EV/EBITDA

0.87

Undervalued EV/EBITDA

-13.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

84.05

Current PS

27.49

Overvalued PS

220.61

Undervalued PS

-52.51

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what penny stocks are people buying

Intellectia · 42 candidates

Market Cap: 50.00M - 2.00BPrice: $0.10 - $5.00Price Change Pct: >= $3.00Relative Vol: >= 1.50Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

EON Resources Inc

67.46M

Beyond Meat Inc

331.79M

Ocugen Inc

767.28M

Upexi Inc

64.91M

Recursion Pharmaceuticals Inc

1.74B

FuboTV Inc

1.50B

news about stocks that are below 10 dollar

Intellectia · 100 candidates

Region: USPrice: $1.00 - $10.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000News Driver: Positive, Negative

Ticker

Name

Market Cap$

XWELL Inc

6.98M

Larimar Therapeutics Inc

494.39M

VS Media Holdings Ltd

5.06M

Evolent Health Inc

350.52M

Navitas Semiconductor Corp

2.27B

Sharplink Inc

1.46B

Best stocks under $5

Intellectia · 498 candidates

Price: $0.50 - $5.00Volume: >= 200,000Market Cap Category: small, micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Newell Brands Inc

1.97B

Recursion Pharmaceuticals Inc

1.82B

Peloton Interactive Inc

1.81B

BigBear.ai Holdings Inc

1.78B

Grupo Televisa SAB

1.77B

FuboTV Inc

1.74B

list top top 20 ai companies

Intellectia · 18 candidates

Themes: AI Beneficiary

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Microsoft Corp

3.30T

Meta Platforms Inc

1.54T

Micron Technology Inc

437.95B

Advanced Micro Devices Inc

406.68B

Palantir Technologies Inc

394.05B

Intellectia · 48 candidates

Market Cap: >= 1000.00MPrice: <= $5.00Weekly Average Turnover: >= 1,000,000Pe Ttm: <= 20

Ticker

Name

Market Cap$

Ambev SA

41.38B

Banco Bradesco SA

39.45B

NIO Inc

11.55B

Aurora Innovation Inc

9.02B

Gerdau SA

8.43B

Energy of Minas Gerais Co

5.98B

which stock is going to skyrocket tomorrow

Intellectia · 41 candidates

Rsi Category: moderateRelative Vol: >= 1.20Analyst Action: UpgradeMoving Average Relationship: PriceCrossAboveMA20

Ticker

Name

Market Cap$

Banco Macro SA

6.27B

Herc Holdings Inc

5.48B

Ci&T Inc

608.04M

Ranger Energy Services Inc

354.89M

Recursion Pharmaceuticals Inc

2.40B

Life Time Group Holdings Inc

6.15B

focus on growth and value

Intellectia · 28 candidates

Market Cap: >= 500.00MPrice: <= $5.00Revenue 5yr Cagr: >= 15Pe Ttm: <= 15

Ticker

Name

Market Cap$

NIO Inc

11.55B

Cosan SA

4.02B

FuboTV Inc

3.33B

Plug Power Inc

3.09B

Recursion Pharmaceuticals Inc

2.40B

Clarivate PLC

1.86B

list only small and medium cap

Intellectia · 3 candidates

Market Cap: 300.00M - 10.00BRelative Vol: >= 1.20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Tetra Tech Inc

9.59B

Recursion Pharmaceuticals Inc

2.40B

Shutterstock Inc

674.53M

List of AI stocks

Intellectia · 17 candidates

Market Cap: >= 1000.00MThemes: AI BeneficiaryBeta: ModerateRisk, HighRiskWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Microsoft Corp

3.30T

Meta Platforms Inc

1.54T

Micron Technology Inc

437.95B

Advanced Micro Devices Inc

406.68B

Palantir Technologies Inc

394.05B

Give a list of potential AI stocks

Intellectia · 17 candidates

Market Cap: >= 1000.00MThemes: AI BeneficiaryBeta: ModerateRisk, HighRiskWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Microsoft Corp

3.30T

Meta Platforms Inc

1.54T

Micron Technology Inc

437.95B

Advanced Micro Devices Inc

406.68B

Palantir Technologies Inc

394.05B

Whales Holding RXRX

SoftBank Group Corp.

Lingotto Investment Management LLP

Allen Holding Inc.

ARK Investment Management LLC

Comprehensive Financial Management LLC

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Recursion Pharmaceuticals Inc (RXRX) stock price today?

The current price of RXRX is 3.07 USD — it has increased 8.1

What is Recursion Pharmaceuticals Inc (RXRX)'s business?

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

What is the price predicton of RXRX Stock?

Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is7.75 USD with a low forecast of 5.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Recursion Pharmaceuticals Inc (RXRX)'s revenue for the last quarter?

Recursion Pharmaceuticals Inc revenue for the last quarter amounts to 35.54M USD, increased 681.74

What is Recursion Pharmaceuticals Inc (RXRX)'s earnings per share (EPS) for the last quarter?

Recursion Pharmaceuticals Inc. EPS for the last quarter amounts to -0.21 USD, decreased -60.38

How many employees does Recursion Pharmaceuticals Inc (RXRX). have?

Recursion Pharmaceuticals Inc (RXRX) has 600 emplpoyees as of April 01 2026.

What is Recursion Pharmaceuticals Inc (RXRX) market cap?

Today RXRX has the market capitalization of 1.62B USD.